James Sandy
Corporate Officer/Principal at F-STAR THERAPEUTICS, INC.
James Sandy active positions
Companies | Position | Start | End |
---|---|---|---|
F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 2022-02-28 | - |
Career history of James Sandy
Former positions of James Sandy
Companies | Position | Start | End |
---|---|---|---|
Ellipses Pharma Ltd.
Ellipses Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ellipses Pharma Ltd. engages in the development of cancer medicines and treatment drugs. The company was founded by Christopher Evans and Rajan Jethwa in April 14, 2015 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - | - |
IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 2015-11-30 | - |
Astra Pharmaceuticals Ltd.
Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Corporate Officer/Principal | - | - |
PFIZER, INC. | Corporate Officer/Principal | - | - |
Creabilis Holdings Ltd.
Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Corporate Officer/Principal | - | - |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Corporate Officer/Principal | 2011-08-22 | - |
Training of James Sandy
Imperial College London | Graduate Degree |
University of Brighton | Undergraduate Degree |
Statistics
International
United Kingdom | 8 |
Italy | 2 |
United States | 2 |
Operational
Corporate Officer/Principal | 7 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
PFIZER, INC. | Health Technology |
IMMUNOCORE HOLDINGS PLC | Health Technology |
Private companies | 5 |
---|---|
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
Creabilis Holdings Ltd.
Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Astra Pharmaceuticals Ltd.
Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Health Technology |
F-star Therapeutics, Inc.
F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Ellipses Pharma Ltd.
Ellipses Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ellipses Pharma Ltd. engages in the development of cancer medicines and treatment drugs. The company was founded by Christopher Evans and Rajan Jethwa in April 14, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- James Sandy
- Experience